Susanne Gulliver

NewLab Clinical Research Inc

Psoriasis is a common, debilitating immune-mediated skin disease. Genetic studies have identified biological mechanisms of psoriasis risk, including those targeted by effective therapies. However, the genetic liability to psoriasis is not fully explained by variation at robustly identified risk loci. To move towards a saturation map of psoriasis su...

Psoriasis is an immune-mediated inflammatory skin disease typically characterized by erythematous and scaly plaques. It affects 3% of the Newfoundland population while only affecting 1.7% of the general Canadian population. Recent genome-wide association studies (GWAS) in psoriasis have identified more than 63 genetic susceptibility loci that indiv...

The Janssen and Newfoundland and Labrador Health Innovation Partnership (JANL-HIP) was established to carry out Real-World Evidence (RWE) projects to generate evidence about disease pathways, healthcare delivery, the effects of clinical interventions. Doing so will support and influence clinical decision-making in Newfoundland and Labrador (NL). Th...

Background Psoriasis is a chronic, immune-mediated inflammatory disease with an implied connection to psychiatric disorders. Objective This study aims to illustrate an association between psoriasis and psychiatric disorders using real world data gathered from the Newfoundland and Labrador population. Methods Data on 15,100 patients with psoriasis...

Background: International Dermatology Outcome Measures (IDEOM) is a non-profit organization founded in 2013. It is composed of researchers and stakeholders who work to develop evidenced-based outcome measures to enhance research and treatment recommendations of dermatologic diseases. Summary: The 2021 IDEOM Virtual Annual Meeting occurred from N...

Background: The incidence of cutaneous malignant melanoma continues to increase worldwide and in Canada. It is unclear whether the increase in incidence and clinical characteristic trends of cutaneous malignant melanoma are similar in the province of Newfoundland and Labrador. Objective: The objective of this study is to examine the incidence an...

Real‐world data for psoriasis includes registries, and meta‐analyses could help guide biologic therapy choice. The objective was to determine the prevalence and reason for discontinuation of biologic or PD4 inhibitor therapy in patients with moderate‐to‐severe psoriasis in Newfoundland and Labrador, Canada from 2001 to 2017. A retrospective cohort...

Introduction: Data on real-world experiences for patients treated with ixekizumab is currently limited. Objectives: Describe characteristics of ixekizumab-treated psoriasis patients and provide evidence of clinical outcomes using disease severity scores Body Surface Area (BSA) and Psoriasis Area and Severity Index (PASI) in the real world. Methods:...

Psoriasis is an inflammatory skin condition affecting 2% to 3% of the population and is associated with several comorbidities, including cardiovascular disease, depression, inflammatory bowel disease, metabolic syndrome, mood disorder, psoriatic arthritis, and weight gain. Psoriasis is treated with a number of topical and systemic therapies, includ...

Plaque psoriasis affects approximately 2% to 3% of the global population, with psoriatic arthritis observed in approximately 20% to 30% of these individuals. Upon advances in research pathophysiology and treatment over the past decade, biologic therapies have been used more to treat moderate to severe psoriasis. In Canada, reimbursement bodies have...

Hidradenitis suppurativa (HS) is an uncommon skin condition that causes painful swollen red bumps in the folds of the body (underarms, under breasts, groin, and buttocks). It can be mistaken for bacterial abscess or boils, but HS is not caused by bacteria. HS occurs in about 0.1–1% people in the US and Europe. The authors include people with HS, de...

化脓性汗腺炎(HS)是一种罕见的皮肤症状,会在皮肤褶皱处(腋下、胸下、腹股沟和臀部)引起疼痛的红色肿块。HS可能会被误诊为细菌性脓肿或烫伤,但它并不是由细菌引起的。HS发生在约0.1~1%的美国和欧洲人中。作者包括来自4大洲、13个国家/地区的HS患者、皮肤科医生、外科医生、制药行业成员和医疗监管机构人员。本项研究旨在找出应衡量哪些HS临床试验,例如症状(如疼痛、瘙痒)、生理变化(如皮肤发红或肿胀)或对人们生活的影响(如生活质量)。为此,本研究包含了两个组:HS患者和保健服务提供者(医生、制药行业代表和监管代表),并采用面对面会议陈述、讨论以及调查的方式进行,以便收集应包含哪些衡量因素的相关意见。会议、讨论和调查的结果表明,至少有70%的HS患者和保健服务提供者建议临床试验包含以下衡量因素:...

Background: A Core Outcomes Set (COS) is an agreed minimum set of outcomes that should be measured and reported in all clinical trials for a specific condition. Hidradenitis suppurativa (HS) has no agreed upon COS. A central aspect in the COS development process is to identify a set of candidate outcome domains from a long list of items. Our long...

Psoriasis is a chronic inflammatory skin condition characterised by the formation of red scaly plaques on the skin. It is an autoimmune disease cause by the dysregulation of cytokines controlling the inflammatory pathways, a mechanism likely contributing to various comorbidities observed in patients with psoriasis. Cardiovascular disease is one com...

Background: Psoriasis is a chronic immune-mediated inflammatory disorder that affects approximately 2% to 3% of the population, which translates to 17 million in North America and Europe and approximately 170 million people worldwide. Although psoriasis can occur at any age, most cases develop before age 40 years. Some larger studies have noted bi...

Over the past decade, biologic therapies have been developed to treat auto-inflammatory conditions such as psoriasis. They have the advantage of better target specificity than traditional systemics such as methotrexate and cyclosporine and therefore significantly reduce side-effects and toxicity associated with wide spread systemic treatments. It h...